Mangoceuticals (NASDAQ: MGRX ) stock climbed up a staggering 130% at one point today after the company announced that its new oral formulations of its Semaglutide (“Slim”) and Tirzepatide (“Trim”) treatments have proven notably effective in clinical trials. What does this mean for MGRX stock?